Skip to main content
Dot gov

Official websites use the Texas HHS logo.
The Texas HHS logo means this is an official website of Texas Health and Human Services.

HTTPS

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

5. References

  1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2024. Accessed September 5, 2024.
  2. Dulaglutide subcutaneous injection (Trulicity) package insert. Eli Lilly and Company, January 2024.
  3. Exenatide regular-release (Byetta) package insert. AstraZeneca Pharmaceuticals, December 2022.
  4. Exenatide extended-release (Bydureon BCise) package insert. AstraZeneca Pharmaceuticals, May 2023.
  5. Liraglutide subcutaneous injection (Victoza) package insert. Novo Nordisk, July 2023.
  6. Semaglutide subcutaneous injection (Ozempic) package insert. Novo Nordisk, September 2023.
  7. Tirzepatide subcutaneous injection (Mounjaro) package insert. Eli Lilly and Company, May 2024.
  8. Semaglutide oral tablets (Rybelsus) package insert. Novo Nordisk, January 2024.
  9. American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes -2024. Diabetes Care. 2024;47(Suppl. 1):S158–S178.
  10. American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes -2024. Diabetes Care. 202;47(Suppl. 1):S179–S218.
  11. Liraglutide subcutaneous injection (Saxenda) package insert. Novo Nordisk, April 2023.
  12. Semaglutide subcutaneous injection (Wegovy) package insert. Novo Nordisk, March 2024.